Bill Gates-Backed IPO Is Among 2019’s Worst Debuts

Bookmark
(Bloomberg) -- Vir Biotechnology Inc. opened 19% below its IPO price in Friday’s debut, extending a pattern of pushback by public investors over the valuations of freshly minted stocks.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.